In the future, biopsies may not always be needed to diagnose nonalcoholic steatohepatitis, according to a new analysis of real-world data. Instead, noninvasive tests may one day offer a less expensive and less burdensome option.
The analysis, from the TARGET-NASH cohort, found that past pathology reports used to identify signs of NASH often are missing documentation of critical diagnostic features, and no matter what information is included, pathologists often disagreed about the severity of various histologic findings indicative of NASH.